MarginsXMarginsX
Home › Markets › Health Care › ACON

Aclarion Inc. (ACON)

ACON trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.39
-12.58% on the day
Market cap
$4.0M
Nano cap
Revenue · 2025
$76K
+65.6% on 2024
Net income · 2025
-$7.2M
-9551.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1635077/000168316826001986/0001683168-26-001986-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerACON on Nasdaq
SectorHealth Care
IndustryMedical Specialities
CountryUnited States
IPO year2022
SEC CIK0001635077

Financials · 2025

LineValue
Revenue$76K
Net income-$7.2M
Operating income-$7.1M
Net margin-9551.9%
Operating margin-9312.5%
Revenue growth+65.6%
Cash$12.0M
Total assets$13.7M
P/E (computed)Net income was not positive
P/S (computed)52.9×

Warning signs

Cash runway
19.0 months
$14.2M cash at September 30, 2026
Share count, 1 year
+329.3%
2025-11-10 to 2026-11-03 · +4743856.7% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$177K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$14.2M cash; operating cash flow -$2.2M a quarter.Report 2026-09-30
Shares outstanding2,882,370 (2026-11-03); 671,371 a year earlier; 8,793,010 three years earlier. 3y figure adjusted for splits (1-for-144720 overall).Cover page 2026-11-03
Reverse splits, 3 years3; latest 1-for-27 on 2025-03-28Source 2025-03-28
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-01-09
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorHaynie & Company, Salt Lake City, Utah, United StatesPCAOB Form AP 2026-03-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $177K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$34K-$2.6M-$2.0M$14.2MNo debt tags$99K10-Q 2026-11-05
Q2 2026
2026-06-30
$25K-$2.7M-$2.7M$16.3MNo debt tags$84K10-Q 2026-08-06
Q1 2026
2026-03-31
$21K-$2.9M-$2.6M$19.0MNo debt tags$78K10-Q 2026-05-13
Q4 2025
2025-12-31
$18K-$1.9M-$1.6M$12.0MNo debt tags$76K10-K 2026-03-18
Q3 2025
2025-09-30
$19K-$1.7M-$1.2M$11.3MNo debt tags$67K10-Q 2026-11-05
Q2 2025
2025-06-30
$19K-$1.6M-$1.9M$12.8MNo debt tags$63K10-Q 2026-08-06
Q1 2025
2025-03-31
$19K-$2.0M-$2.5M$14.8MNo debt tags$55K10-Q 2026-05-13
Q4 2024
2024-12-31
$10K-$2.0M-$923K$454K$0$46K10-K 2026-03-18

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-6.0%
1 month-27.1%
3 months-35.0%
Year to date-66.1%
1 year-74.6%
From 52-week high-80.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
ACONWAclarion Inc. Warrant$0.0214

Peers in Medical Specialities

TickerCompanyPriceDayMarket cap
ADVBAdvanced Biomed Inc.$2.22-12.25%$3.7M
ACHAccendra Health Inc.$0.0857-35.08%$6.6M
BGLCBioNexus Gene Lab Corp$0.8200-0.12%$2.4M
AMSAmerican Shared Hospital Services$1.07-0.93%$7.1M
MDXHMDxHealth SA$0.1490+3.40%$14.2M
SERASera Prognostics Inc.$1.94-3.48%$77.2M
XGNExagen Inc.$3.77-8.72%$96.2M
BDSXBiodesix Inc.$9.00-8.91%$99.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier